Baxter International Inc. Share Price Berne S.E.

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Delayed Berne S.E. 09:30:00 06/04/2023 pm IST 5-day change 1st Jan Change
38.11 CHF +3.50% Intraday chart for Baxter International Inc. -.--% -.--%

Financials

Sales 2024 * 1.51TCr 1.35TCr 1,26200Cr Sales 2025 * 1.57TCr 1.4TCr 1,30800Cr Capitalization 1.74TCr 1.55TCr 1,45000Cr
Net income 2024 * 70Cr 63Cr 5.87TCr Net income 2025 * 95Cr 85Cr 7.93TCr EV / Sales 2024 * 1.8 x
Net Debt 2024 * 984.69Cr 880.06Cr 82TCr Net Debt 2025 * 905.57Cr 809.35Cr 76TCr EV / Sales 2025 * 1.69 x
P/E ratio 2024 *
18.5 x
P/E ratio 2025 *
15.2 x
Employees -
Yield 2024 *
3.51%
Yield 2025 *
3.64%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 01/15/01
Director of Finance/CFO 54 18/23/18
Chief Tech/Sci/R&D Officer - 01/17/01
Members of the board TitleAgeSince
Director/Board Member 73 06/17/06
Director/Board Member 64 10/22/10
Director/Board Member 64 18/19/18
More insiders
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
34.08 USD
Average target price
45.44 USD
Spread / Average Target
+33.33%
Consensus